SMC research team to prove therapeutic effect of intravenous ferric carboxymaltose for treatment of anemia in cancer patients
Professor Junho Jang of Division of hematology-oncology at SMC recently published a paper in PLOS Medicine (IF 11.048) on effective of intravenous ferric carboxymaltose in the treatment of anemia, which is commonly found in cancer patients.
Anemia is the most common cancer-related complication, and in cancer patients receiving chemotherapy, anemia not only disrupts survival and treatment effectiveness, but also reduces the quality of life. Therefore, proper management of anemia in cancer patients is critical. In the past, blood transfusion and EPO therapy have been used to treat anemia.
Iron deficiency commonly found in cancer patients is particularly associated with the hepcidin level, and prof. Junho Jang applied the intravenous ferric carboxymaltose to cancer patients with anemia, which resulted in an increase of a hemoglobin level in 70% of the patients. In addition, the research team found that the hepcidin level can be used as an important biomarker for determination of the need for iron treatment in cancer patients with anemia.
This study was the first to demonstrate the effect of IV Iron in treatment of anemia in cancer patients, and it is meaningful in that the study was a prospective investigator-initiated trial carried out at SMC. Based on results of this study, Jang has started a phase 3 clinical study.